Internal

Our Position on Science

We believe...

emerging science and new technologies are creating new opportunities to transform the practice of medicine.


We offer...

We ask...

a combination of cutting-edge technologies and expertise that fuel our robust pipeline.

A deep knowledge of the biology of disease pathways in immunology and monogenic disorders will lead to the development of new treatments that make a meaningful difference in the lives of patients.

- Translating scientific knowledge into cutting-edge therapies that change the practice of medicine requires new platforms such as those based on Nanobodies®, mRNA, gene therapy or synthetic biology.
- An understanding of patient experience is critical to pioneering innovation, as is the development of outstanding digital R&D capabilities.
- Biopharmaceutical science has significant potential to create economic value and highly skilled jobs and to be a leading driver in building the economy of this century.
- Thanks to our science millions of people have the possibility to access our medicines and vaccines every year (e.g., 500 million people vaccinated annually).
- Our unique disease insights stand out in human immunology (vaccines, multiple sclerosis, immuneoncology, immunology & inflammation) and monogenic disorders (rare genetic diseases, hemophilia).
- Our strategic decisions are advancing our scientific progress by improving efficiency, accelerating the pace of our decision making and making strategic acquisitions (Ablynx, Synthorx, Kiadis and Principia) that give us access to next generation therapeutic platforms.
- We are transforming our R&D engine; with a strong increase of Sanofi's assets in development (75%) with the potential to be the best therapeutic solution for patients in our prioritized therapeutic areas. Likewise, approximately 65% of Sanofi's drug candidates come from in-house research and development.
- We are enhancing speed and efficiency of our drug discovery efforts by integrating digital technologies and approaches such as artificial intelligence, machine learning and real-world evidence.
- Governments to protect intellectual property rights to accelerate and create a receptive environment for scientific breakthroughs.
- Governments to adopt policies that encourage and boost the biopharma ecosystem and reward innovation that has the potential to make a meaningful difference in therapeutic areas with significant patient needs.
- Governments to promote sustainable dialogue with the private sector and implement public-private-partnership initiatives to accelerate translation of valuable scientific



for fair recognition of our efforts to

transform the practice of medicine.